|
Ortho Evra is a thin, flexible,
transdermal women’s birth control patch applied to the lower
abdomen, buttocks or upper body once a week. The Ortho Evra
patch delivers a continuous flow of estrogen and progestin
to prevent ovulation. The patch is used for three weeks, and
then stopped for one week to allow menstruation. Ortho Evra
contains the same drugs as typical birth control pills;
however, the way the drug is administered exposes women to
much higher levels of estrogen.
In November 2005, The Food and
Drug Administration approved a new warning label for Ortho
Evra, stating in bold letters that the patch exposes women
to about 60 percent more estrogen than the birth control
pill. The makers of Ortho Evra, Ortho-McNeil, previously
failed to warn users of the higher estrogen levels, which
may increase the risk of heart attack, stroke, pulmonary
embolism, deep vein thrombosis and death.
Ortho Evra is the first and
only skin patch approved for birth control, and more than 4
million women have used the patch since it came on the
market. The patch releases ethinyl estradiol, an estrogen
hormone, and norelgestromin, a progestin hormone, through
the skin into the bloodstream. It only needs to be changed
once a week.
However, in July 2005 the
Associated Press reported that, according to FDA records it
obtained through a Freedom of Information Act, women using
Ortho Evra in 2004 were three times as likely as women using
birth control pills to die or develop nonfatal blood clots.
The Associated Press learned that of the 23 cases in which
death was the outcome, doctors reviewing the cases found 17
that appeared to be blood-clot-related, including 12 in
2004.
Since the FDA estimates that
it receives reports of only between 1 percent and 10 percent
of the serious adverse drug reactions that actually occur,
the death rate for Ortho Evra may be significantly higher.
The Ortho Evra patch, which
is available by prescription only, has not yet been pulled
off the market. The drug maker says it is launching its own
study with input from the FDA to assess the dangers of using
the patch. Women who may be using Ortho Evra should contact
their physician if any of the following warning signals
develop:
- Sharp chest pain,
coughing of blood, or sudden shortness of breath
(indicating a possible clot in the lung)
- Pain in the calf
(indicating a possible clot in the leg)
- Crushing chest pain or
tightness in the chest (indicating a possible heart
attack)
- Sudden severe headache
or vomiting, dizziness or fainting, disturbances of
vision or speech, weakness, or numbness in an arm or leg
(indicating a possible stroke)
- Sudden partial or
complete loss of vision (indicating a possible clot in
the eye)
- Breast lumps (indicating
possible breast cancer or fibrocystic disease of the
breast; ask your doctor or health care professional to
show you how to examine your breasts)
- Severe pain or
tenderness in the stomach area (indicating a possibly
ruptured liver tumor)
- Severe problems with
sleeping, weakness, lack of energy, fatigue, or change
in mood (possibly indicating severe depression)
- Jaundice or a yellowing
of the skin or eyeballs accompanied frequently by fever,
fatigue, loss of appetite, dark colored urine, or light
colored bowel movements (indicating possible liver
problems)
Younce & Vtipil is devoted to
assisting people who have suffered serious Ortho Evra side
effects. If you or a loved one has experienced a heart
attack, stroke, or serious clot while using the Ortho Evra
patch, you may want to consider your potential legal claim
for this loss.
At Younce & Vtipil, it will
cost you nothing to speak with an attorney about your
potential claim and there is no obligation when you call. We
are typically paid on a contingent fee basis, meaning that
we are not paid until we successfully obtain money for our
client. If we can be of service to you, your family or
friends, please do not hesitate to call us at 1-800-811-9495
or contact us online. |